Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 14.40
NAS:CPIX's Cash to Debt is ranked higher than
60% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. NAS:CPIX: 14.40 )
Ranked among companies with meaningful Cash to Debt only.
NAS:CPIX' s Cash to Debt Range Over the Past 10 Years
Min: 1.16  Med: 13.41 Max: No Debt
Current: 14.4
Equity to Asset 0.85
NAS:CPIX's Equity to Asset is ranked higher than
86% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NAS:CPIX: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
NAS:CPIX' s Equity to Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.85 Max: 0.91
Current: 0.85
0.42
0.91
F-Score: 4
Z-Score: 4.95
M-Score: -2.75
WACC vs ROIC
6.70%
-0.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -0.55
NAS:CPIX's Operating margin (%) is ranked lower than
75% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.44 vs. NAS:CPIX: -0.55 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:CPIX' s Operating margin (%) Range Over the Past 10 Years
Min: -11.87  Med: 13.72 Max: 23.96
Current: -0.55
-11.87
23.96
Net-margin (%) -0.07
NAS:CPIX's Net-margin (%) is ranked lower than
73% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. NAS:CPIX: -0.07 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:CPIX' s Net-margin (%) Range Over the Past 10 Years
Min: -6.57  Med: 9.08 Max: 24.72
Current: -0.07
-6.57
24.72
ROE (%) -0.03
NAS:CPIX's ROE (%) is ranked lower than
69% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.76 vs. NAS:CPIX: -0.03 )
Ranked among companies with meaningful ROE (%) only.
NAS:CPIX' s ROE (%) Range Over the Past 10 Years
Min: -2.55  Med: 6.91 Max: 50.74
Current: -0.03
-2.55
50.74
ROA (%) -0.03
NAS:CPIX's ROA (%) is ranked lower than
68% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. NAS:CPIX: -0.03 )
Ranked among companies with meaningful ROA (%) only.
NAS:CPIX' s ROA (%) Range Over the Past 10 Years
Min: -2.26  Med: 5.3 Max: 24.03
Current: -0.03
-2.26
24.03
ROC (Joel Greenblatt) (%) 0.87
NAS:CPIX's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.07 vs. NAS:CPIX: 0.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:CPIX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -43.4  Med: 92.21 Max: 1721.07
Current: 0.87
-43.4
1721.07
Revenue Growth (3Y)(%) -7.40
NAS:CPIX's Revenue Growth (3Y)(%) is ranked lower than
80% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. NAS:CPIX: -7.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:CPIX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.4  Med: 3.25 Max: 47.3
Current: -7.4
-7.4
47.3
EBITDA Growth (3Y)(%) -25.60
NAS:CPIX's EBITDA Growth (3Y)(%) is ranked lower than
90% of the 564 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.30 vs. NAS:CPIX: -25.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:CPIX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.6  Med: 2.5 Max: 109
Current: -25.6
-25.6
109
EPS Growth (3Y)(%) -48.90
NAS:CPIX's EPS Growth (3Y)(%) is ranked lower than
95% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. NAS:CPIX: -48.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:CPIX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.9  Med: -14.3 Max: 34.2
Current: -48.9
-48.9
34.2
» NAS:CPIX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CPIX Guru Trades in Q3 2015

Jim Simons 198,580 sh (+0.96%)
Chuck Royce 14,600 sh (unchged)
John Rogers 1,484,096 sh (-1.39%)
» More
Q4 2015

CPIX Guru Trades in Q4 2015

Jim Simons 217,200 sh (+9.38%)
Chuck Royce Sold Out
John Rogers 1,416,660 sh (-4.54%)
» More
Q1 2016

CPIX Guru Trades in Q1 2016

John Rogers 1,976,671 sh (+39.53%)
Jim Simons 222,600 sh (+2.49%)
» More
Q2 2016

CPIX Guru Trades in Q2 2016

Jim Simons 235,300 sh (+5.71%)
John Rogers 1,992,613 sh (+0.81%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:GALT, OTCPK:ZOMHF, NAS:STDY, NAS:EPIX, NAS:LPCN, NAS:ADMP, NAS:SCYX, OTCPK:WUYIF, NAS:SPHS, NAS:JNP, NAS:ARDM, OTCPK:NRIFF, NAS:MEIP, NAS:CPHR, OTCPK:MQTRF, NAS:CPRX, NAS:PTX, NAS:SMMT, NAS:PSDV, NAS:OREX » details
Traded in other countries:CBJ.Germany,
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the acquisition, development and commercialization of branded prescription products. Its target markets are hospital acute care and gastroenterology.

Cumberland Pharmaceuticals Inc., was incorporated in Tennessee on January 6, 1999. It is a specialty pharmaceutical company which is engaged in the acquisition, development and commercialization of branded prescription products. It operates in a single operating segment of specialty pharmaceuticals products. Its product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS). The Company's target markets are hospital acute care and gastroenterology, which are characterized by concentrated physician bases that it believe can be penetrated effectively by relatively small, targeted sales forces. The Company markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised more than 65 sales representatives and managers as of March 1, 2013. Acetadote is an intravenous formulation of N-acetylcysteine, or NAC, indicated for the treatment of acetaminophen poisoning. Caldolor, its intravenous formulation of ibuprofen, was the first injectable product approved in the United States for the treatment of both pain and fever. Kristalose is a prescription laxative administered orally for the treatment of constipation. Hepatoren is in Phase II clinical development. Pharmaceutical companies are subject to extensive regulation by national, state, and local agencies in the U.S. and additional regulations in other countries in which do business. It promotes Acetadote and Caldolor through its dedicated hospital sales team and currently utilize two distinct sales teams to address its primary target markets: a hospital sales force for the acute care market and a field sales force for the gastroenterology market. It competes with the product attributes such as efficacy, safety, ease-of-use and cost-effectiveness.

Ratios

vs
industry
vs
history
P/B 1.06
CPIX's P/B is ranked higher than
84% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. CPIX: 1.06 )
Ranked among companies with meaningful P/B only.
CPIX' s P/B Range Over the Past 10 Years
Min: 0.9  Med: 1.3 Max: 4.83
Current: 1.06
0.9
4.83
P/S 2.61
CPIX's P/S is ranked higher than
53% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. CPIX: 2.61 )
Ranked among companies with meaningful P/S only.
CPIX' s P/S Range Over the Past 10 Years
Min: 1.66  Med: 2.6 Max: 6.8
Current: 2.61
1.66
6.8
PFCF 608.75
CPIX's PFCF is ranked lower than
97% of the 193 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.56 vs. CPIX: 608.75 )
Ranked among companies with meaningful PFCF only.
CPIX' s PFCF Range Over the Past 10 Years
Min: 12.85  Med: 31.11 Max: 1903.33
Current: 608.75
12.85
1903.33
POCF 66.71
CPIX's POCF is ranked lower than
88% of the 256 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.62 vs. CPIX: 66.71 )
Ranked among companies with meaningful POCF only.
CPIX' s POCF Range Over the Past 10 Years
Min: 11.4  Med: 19.15 Max: 1583.33
Current: 66.71
11.4
1583.33
EV-to-EBIT 1000.69
CPIX's EV-to-EBIT is ranked lower than
100% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.31 vs. CPIX: 1000.69 )
Ranked among companies with meaningful EV-to-EBIT only.
CPIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.8  Med: 10.95 Max: 1059.8
Current: 1000.69
-17.8
1059.8
EV-to-EBITDA 13.88
CPIX's EV-to-EBITDA is ranked higher than
60% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.21 vs. CPIX: 13.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
CPIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -56.6  Med: 8.4 Max: 35.6
Current: 13.88
-56.6
35.6
Shiller P/E 24.84
CPIX's Shiller P/E is ranked higher than
77% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.59 vs. CPIX: 24.84 )
Ranked among companies with meaningful Shiller P/E only.
CPIX' s Shiller P/E Range Over the Past 10 Years
Min: 21.7  Med: 23.3 Max: 31
Current: 24.84
21.7
31
Current Ratio 7.19
CPIX's Current Ratio is ranked higher than
86% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. CPIX: 7.19 )
Ranked among companies with meaningful Current Ratio only.
CPIX' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 5.83 Max: 14.46
Current: 7.19
1.45
14.46
Quick Ratio 6.64
CPIX's Quick Ratio is ranked higher than
86% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. CPIX: 6.64 )
Ranked among companies with meaningful Quick Ratio only.
CPIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.36 Max: 13.46
Current: 6.64
1.38
13.46
Days Inventory 328.53
CPIX's Days Inventory is ranked lower than
94% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.00 vs. CPIX: 328.53 )
Ranked among companies with meaningful Days Inventory only.
CPIX' s Days Inventory Range Over the Past 10 Years
Min: 92.58  Med: 381.63 Max: 636.33
Current: 328.53
92.58
636.33
Days Sales Outstanding 53.46
CPIX's Days Sales Outstanding is ranked higher than
70% of the 579 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.08 vs. CPIX: 53.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.88  Med: 51.09 Max: 104.9
Current: 53.46
30.88
104.9
Days Payable 270.50
CPIX's Days Payable is ranked higher than
95% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.81 vs. CPIX: 270.50 )
Ranked among companies with meaningful Days Payable only.
CPIX' s Days Payable Range Over the Past 10 Years
Min: 103.04  Med: 225.25 Max: 513.19
Current: 270.5
103.04
513.19

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 4.70
CPIX's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. CPIX: 4.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CPIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7  Med: 0.6 Max: 5.1
Current: 4.7
-7
5.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.13
CPIX's Price/Net Cash is ranked higher than
93% of the 201 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.90 vs. CPIX: 2.13 )
Ranked among companies with meaningful Price/Net Cash only.
CPIX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.37  Med: 2.16 Max: 6.72
Current: 2.13
1.37
6.72
Price/Net Current Asset Value 1.57
CPIX's Price/Net Current Asset Value is ranked higher than
93% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.54 vs. CPIX: 1.57 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CPIX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.07  Med: 1.66 Max: 5.38
Current: 1.57
1.07
5.38
Price/Tangible Book 1.48
CPIX's Price/Tangible Book is ranked higher than
80% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. CPIX: 1.48 )
Ranked among companies with meaningful Price/Tangible Book only.
CPIX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.04  Med: 1.59 Max: 5.21
Current: 1.48
1.04
5.21
Price/Projected FCF 1.05
CPIX's Price/Projected FCF is ranked higher than
84% of the 287 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.65 vs. CPIX: 1.05 )
Ranked among companies with meaningful Price/Projected FCF only.
CPIX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.73  Med: 1.11 Max: 1.59
Current: 1.05
0.73
1.59
Price/Median PS Value 1.01
CPIX's Price/Median PS Value is ranked higher than
62% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. CPIX: 1.01 )
Ranked among companies with meaningful Price/Median PS Value only.
CPIX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.66  Med: 1.04 Max: 2.49
Current: 1.01
0.66
2.49
Earnings Yield (Greenblatt) (%) 0.10
CPIX's Earnings Yield (Greenblatt) (%) is ranked lower than
70% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. CPIX: 0.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CPIX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 7.6 Max: 79.2
Current: 0.1
0.1
79.2
Forward Rate of Return (Yacktman) (%) -0.39
CPIX's Forward Rate of Return (Yacktman) (%) is ranked lower than
66% of the 330 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.64 vs. CPIX: -0.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CPIX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -0.4  Med: 3.6 Max: 18
Current: -0.39
-0.4
18

More Statistics

Revenue (TTM) (Mil) $31.08
Beta0.68
Short Percentage of Float0.60%
52-Week Range $4.20 - 6.50
Shares Outstanding (Mil)16.23
» More Articles for NAS:CPIX

Headlines

Articles On GuruFocus.com
Micro Cap Value Discovery Jul 05 2016 
Speculative Options Buys Apr 29 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 16 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) May 17 2010 

More From Other Websites
Cumberland Pharmaceuticals Launches Promotion Of Ethyol® In The United States For Oncology Patient... Sep 26 2016
Clinigen Group and Cumberland Pharmaceuticals launch Ethyol® in the U.S. Sep 26 2016
8:34 am Cumberland Pharma launches promotion of Ethyol in the US for oncology patient support Sep 26 2016
Cumberland Pharmaceuticals Launches Promotion Of Ethyol® In The United States For Oncology Patient... Sep 26 2016
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Sep 16 2016
Cumberland Pharmaceuticals Announces New Program To Develop Portaban™ For Portal Hypertension Sep 14 2016
Cumberland Pharmaceuticals Announces New Program To Develop Portaban™ For Portal Hypertension Sep 14 2016
ETF’s with exposure to Cumberland Pharmaceuticals, Inc. : September 8, 2016 Sep 08 2016
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Aug 26 2016
Cumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For Oncology Patient... Aug 23 2016
Cumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For Oncology Patient... Aug 23 2016
CUMBERLAND PHARMACEUTICALS INC Financials Aug 13 2016
ETF’s with exposure to Cumberland Pharmaceuticals, Inc. : August 11, 2016 Aug 11 2016
Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9,... Aug 09 2016
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 05 2016
CUMBERLAND PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 05 2016
Cumberland posts 2Q loss Aug 02 2016
Cumberland posts 2Q loss Aug 02 2016
Edited Transcript of CPIX earnings conference call or presentation 2-Aug-16 8:30pm GMT Aug 02 2016
Cumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results Aug 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)